NASDAQ:ESLA Estrella Immunopharma (ESLA) Stock Price, News & Analysis $0.38 -0.13 (-26.07%) Closing price 04:00 PM EasternExtended Trading$0.38 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Estrella Immunopharma Stock (NASDAQ:ESLA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Estrella Immunopharma alerts:Sign Up Key Stats Today's Range$0.38▼$0.5250-Day Range$0.31▼$0.9952-Week Range$0.24▼$2.33Volume529,195 shsAverage Volume662,165 shsMarket Capitalization$16.53 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingHold Company Overview Estrella Immunopharma is a clinical-stage biotechnology company developing T-cell therapies for cancer and autoimmune diseases. Its approach is designed to direct a patient’s immune cells to recognize and attack disease-associated targets. The company’s lead program, EB103, is an investigational T-cell therapy that targets CD19, a protein found on certain B cells. Estrella is developing the treatment for B-cell malignancies, including non-Hodgkin lymphoma. Its programs use the ARTEMIS platform, which was developed by Eureka Therapeutics. Estrella was established in 2021 and became publicly traded following a business combination with TradeUP Acquisition Corp. The company is based in the United States; detailed information about its geographic operations and current leadership is not included here.AI Generated. May Contain Errors. Read More Estrella Immunopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreESLA MarketRank™: 1.88386583587 of 5 starsEstrella Immunopharma scored higher than 38% of companies evaluated by MarketBeat, and ranked 703rd out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingEstrella Immunopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialEstrella Immunopharma has a consensus price target of $8.00, representing about 1,605.8% upside from its current price of $0.47.Amount of Analyst CoverageEstrella Immunopharma has only been the subject of 1 research reports in the past 90 days.Read more about Estrella Immunopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Estrella Immunopharma are expected to decrease in the coming year, from ($0.25) to ($0.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Estrella Immunopharma is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Estrella Immunopharma is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Estrella Immunopharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.27% of the float of Estrella Immunopharma has been sold short.Short Interest Ratio / Days to CoverEstrella Immunopharma has a short interest ratio ("days to cover") of 0.37, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Estrella Immunopharma has recently increased by 54.92%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEstrella Immunopharma does not currently pay a dividend.Dividend GrowthEstrella Immunopharma does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.39 News SentimentEstrella Immunopharma has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Estrella Immunopharma this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ESLA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Estrella Immunopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Estrella Immunopharma insiders have not sold or bought any company stock.Percentage Held by Insiders5.80% of the stock of Estrella Immunopharma is held by insiders.Percentage Held by Institutions0.35% of the stock of Estrella Immunopharma is held by institutions.Read more about Estrella Immunopharma's insider trading history. Receive ESLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Estrella Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ESLA Stock News HeadlinesEstrella Immunopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 202641 minutes ago | marketscreener.comMEstrella Immunopharma Names Cynthia Pussinen CEO, Succeeding Cheng LiuOctober 28, 2026 | rttnews.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 16 at 1:00 AM | Behind the Markets (Ad)Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of DirectorsOctober 26, 2026 | finance.yahoo.comEstrella Immunopharma (ESLA) stock soars 18%: what's driving the surgeOctober 22, 2026 | msn.comEstrella Immunopharma, Inc. Activates Intermountain Health LDS Hospital As Fifth Clinical Site For Phase I/II STARLIGHT-1 Trial In B-Cell Non-Hodgkin?s LymphomaOctober 16, 2026 | marketscreener.comMEstrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion PhaseOctober 15, 2026 | finance.yahoo.comEstrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaOctober 14, 2026 | finance.yahoo.comSee More Headlines ESLA Stock Analysis - Frequently Asked Questions How have ESLA shares performed this year? Estrella Immunopharma's stock was trading at $1.56 at the beginning of the year. Since then, ESLA shares have decreased by 69.9% and is now trading at $0.4690. How were Estrella Immunopharma's earnings last quarter? Estrella Immunopharma, Inc. (NASDAQ:ESLA) announced its quarterly earnings results on Saturday, May, 16th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.03. How do I buy shares of Estrella Immunopharma? Shares of ESLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today11/16/2026Next Earnings (Estimated)12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 7 days, ESLA's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ESLA CIK1844417 Webwww.estrellabio.com Phone510-318-9098FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Price Target for Estrella Immunopharma$8.00 High Price Target$8.00 Low Price Target$8.00 Potential Upside/Downside+1,946.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.06 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-328.72% Debt Debt-to-Equity RatioN/A Current Ratio0.20 Quick Ratio0.20 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / Book-1.45Miscellaneous Outstanding Shares43,500,000Free Float40,975,000Market Cap$17.01 million OptionableNot Optionable Beta0.88 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ESLA) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.